Company Overview

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering and developing life-changing treatments for patients with under-addressed neuropsychiatric, neurological, and neuroendocrine disorders. Founded in January 1992 and headquartered in San Diego, California, the company's simple purpose is to relieve suffering for people with great needs. As of October 11, 2024, the company is led by CEO Kyle Gano.

Financial Performance and Market Position

Neurocrine Biosciences has demonstrated strong financial performance, particularly driven by its flagship product, INGREZZA. The company's market capitalization stands at $13.93 billion as of recent trading.

Recent Financial Results

- Q4 2024 Performance:

- INGREZZA net product sales reached $615 million.

- Full-year 2024 sales for INGREZZA totaled $2.3 billion, representing a year-over-year growth of 23% and 26% respectively.

- Q2 2025 Performance:

- INGREZZA achieved $624 million in net product sales, reflecting 15% sequential growth over Q1 2025 and 8% growth year-over-year. This was driven by strong patient demand and a new quarterly record in new prescriptions.

Stock Performance

- All-Time High: $157.98 (August 1, 2024)

- All-Time Low: $1.94 (November 30, 2009)

- Beta Coefficient: 0.64

- Volatility: 1.03%

Product Portfolio and Key Medications

Neurocrine Biosciences has developed a robust portfolio of treatments and a promising pipeline targeting significant unmet medical needs in neuroscience.

Flagship Product: INGREZZA

INGREZZA is the company's primary commercial product, approved for tardive dyskinesia and chorea associated with Huntington's disease. Its approval in the U.S. for tardive dyskinesia was in 2017.

Additional Commercial Products

The company's portfolio also includes:

- ALKANDI for adrenal insufficiency.

- Efmody capsules for classic congenital adrenal hyperplasia.

- Orilissa tablets for endometriosis.

- Oriahnn capsules to treat uterine fibroids.

- CRENESSITY to treat congenital adrenal hyperplasia.

Recent FDA Approval: CRENESSITY

CRENESSITY received FDA approval in December 2024 as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). This marks the first new treatment for the CAH community in over 70 years. CRENESSITY generated $14.5 million in Q1 2025 net product sales, with strong initial patient demand.

Development Pipeline

Neurocrine Biosciences is actively advancing its pipeline through various stages of clinical development.

Late-Stage Programs

- Osavampator (formerly NBI-1065845 / TAK-653): The company initiated a Phase 3 program for this potential first-in-class AMPA positive allosteric modulator for patients with major depressive disorder (MDD) who have an inadequate response to existing treatments. Neurocrine will hold exclusive global rights (except Japan) for its development and commercialization through an amended collaboration with Takeda.

- NBI-568: Ongoing registrational programs include NBI-568, a selective M4 muscarinic agonist, for schizophrenia.

Early-Stage Research

- NBIP-1435: A Phase 1 study commenced for this long-acting corticotropin-releasing factor type 1 (CRF-1) receptor antagonist administered via subcutaneous injection for the potential treatment of congenital adrenal hyperplasia.

Therapeutic Focus Areas

The company's therapeutic focus areas span several complex neurological and endocrine disorders. Its diverse portfolio includes U.S. FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The pipeline is robust, with multiple compounds in mid- to late-phase clinical development.

The company is also developing treatments for Parkinson's disease and Tourette syndrome, and with a partner for endometriosis and uterine fibroids.

Market Position and Competitive Advantages

For three decades, Neurocrine Biosciences has leveraged its unique insights into neuroscience and the interconnectedness of brain and body systems to treat complex conditions. The company is relentless in its pursuit of medicines to ease the burden of debilitating diseases. A key competitive advantage is the expanded formulary access for INGREZZA, significantly improving coverage to include two-thirds of tardive dyskinesia and Huntington's disease Medicare beneficiaries.

Future Outlook

Management expresses confidence in the company's trajectory, citing a "rapidly advancing and growing pipeline and a strong financial profile," positioning them "well to build a leading neuroscience company."

The company plans to host an R&D Day in San Diego on December 16, 2025, which is expected to provide further insights into their pipeline and strategic direction.

Neurocrine Biosciences represents a mature biopharmaceutical company with a strong commercial foundation in INGREZZA, recent expansion through CRENESSITY's launch, and a promising pipeline focused on addressing significant unmet medical needs in neuroscience.